Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 8/20 | 0.44 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094820 | 1.00 | CYP3A4 (0.47) | CYP3A4TSHRUSP2HSD17B10CES2 | |
| SCHEMBL13181609 | 0.88 | USP2 (0.43) | CYP3A4TSHRUSP2TACR1 | |
| SCHEMBL3094857 | 0.75 | CES2 (0.53) | CYP3A4TSHRUSP2HSD17B10CES2 | |
| SCHEMBL3094854 | 0.75 | CES2 (0.53) | CYP3A4TSHRUSP2HSD17B10CES2 | |
| SCHEMBL6441435 | 0.73 | RHOA (0.51) | CYP3A4TSHRUSP2HSD17B10TACR1 | |
| SCHEMBL6441438 | 0.73 | RHOA (0.51) | CYP3A4TSHRUSP2HSD17B10TACR1 | |
| SCHEMBL3096904 | 0.72 | CES2 (0.50) | CYP3A4TSHRUSP2CES2TACR1 | |
| SCHEMBL3091750 | 0.71 | CES2 (0.48) | CYP3A4TSHRUSP2HSD17B10CES2 | |
| SCHEMBL7862741 | 0.71 | TACR1 (0.47) | CYP3A4TSHRUSP2HSD17B10TACR1 | |
| SCHEMBL3660211 | 0.71 | CNR2 (0.71) | CES2P2RX1TACR1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799934-B2 | Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | UNIVERSITY OF SOUTH FLORIDA OF TAMPA | 2009-01-29 | — | — | US | disclosed |
| WO-2009005775-A2 | ENANTIOSELECTIVE RING-OPENING OF AZIRIDINES | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | AZI2, ITPA, ADORA2A | CYP3A4 936/4885TSHR 1539/4885USP2 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.